Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bleyer WA, O’Leary M, Barr R, Ries LAG (eds) (2006) Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival, 1975–2000. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda MD; also available at www.seer.cancer.gov/publications
Birch JM, Alston RD, Quinn M, Kelsey AM (2003) Incidence of malignant disease by morphological type, in young persons aged 12–24 years in England, 1979–1997. Eur J Cancer 39:2622–2631
Perkins SL, Raphael M, McCarthy K, et al (2003) Pediatric mature B-cell lymphoma: distribution of lymphoma subtype varies between national groups. Results from the FAB/LMB96 International Cooperative Group Study. Blood 102:1428 (abstract)
Jaffe E, Harris N, Stein H, Vardiman J (eds) (2000) World Health Organization Classifiction of Tumors. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Washington DC
Harris N, Jaffe E, Stein H, et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392
Shipp MA, Ross KN, Tamayo P, et al (2002) Diffuse large B-cell lymphoma outcome prediction by geneexpression profiling and supervised machine learning. Nat Med 8:68–74
Murphy SB (1980) Classification, staging and end results of treatment of childhood non-Hodgkin lymphoma: dissimilarities from lymphomas in adults. Semin Oncol 7:332–339
Patte C, Sakiroglu C, Ansoborlo S, et al (2002) Urateoxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Francaise d’Oncologie Pédiatrique LMB89 protocol. Ann Oncol 13:789–795
Pui CH, Mahmoud HH, Wiley JM, et al (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19:697–704
Goldman SC, Holcenberg JS, Finklestein JZ, et al (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97:2998–3003
Coiffier B, Mounier N, Bologna S, et al (2003) Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 21:4402–4406
Patte C, Philip T, Rodary C, et al (1986) Improved survival rate in children with stage III and IV B cell non-Hodgkin lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 4:1219–1226
Patte C, Philip T, Rodary C, et al (1991) High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9:123–132
Patte C, Auperin A, Michon J, et al (2001) The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370–3379
Reiter A, Schrappe M, Parwaresch R, et al (1995) Non-Hodgkin lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage — a report of the Berlin-Frankfurt-Munster group. J Clin Oncol 13:359–372
Reiter A, Schrappe M, Tiemann M, et al (1999) Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHLBFM 90. Blood 94:3294–3306
Magrath I, Adde M, Shad A, et al (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925–934
Atra A, Gerrard M, Hobson R, et al (1998) Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin lymphoma (B-NHL) — results of the UKCCSG 9003 protocol. Br J Cancer 77:2281–2285
Atra A, Imeson JD, Hobson R, et al (2000) Improved outcome in children with advanced stage B-cell non-Hodgkin lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 82:1396–1402
Spreafico F, Massimino M, Luksch R, et al (2002) Intensive, very short-term chemotherapy for advanced Burkitt lymphoma in children. J Clin Oncol 20:2783–2788
Murphy SB, Hustu HO, Rivera G, Berard CW (1983) End results of treating children with localized non-Hodgkin lymphomas with a combined modality approach of lessened intensity. J Clin Oncol 1:326–330
Link MP, Shuster JJ, Donaldson SS, et al (1997) Treatment of children and young adults with early-stage non-Hodgkin lymphoma. N Engl J Med 337:1259–1266
Meadows AT, Sposto R, Jenkin RD, et al (1989) Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol 7:92–99
Gerrard M, Cairo MS, Patte C, et al (2003) Results of the FAB international study in children and adolescents (C+A) with localised B-NHL (large cell [LCL], Burkitt [BL] and Burkitt-like [BLL]). Proc ASCO 22:795 (abstract)
Reiter A, Schrappe M, Zimmermann M, et al (2003) Randomized trial of high dose methotrexate I.V. infusion over 24 hours versus 4 hours as part of combination chemotherapy for childhood and adolescent B-cell neoplasms. A report of the BFM Group. J Pediatr Hematol Oncol 25:S2 (abstract)
Patte C, Gerrard M, Auperin A, et al (2003) Early treatment intensity has a major prognostic impact in the “intermediate risk” childhood and adolescent B-cell lymphoma: results of the international FAB LMB 96 trial. Blood 102:491 (abstract)
Pusill-Wachtsmuth B, Zimmermann M, Seidemann K, et al (2003) Non-Hodgkin-lymphoma of adolescence: treatment results in the pediatric multicenter studies NHL-BFM. J Pediatr Hematol Oncol 25:S2 (abstract)
Todeschini G, Tecchio C, Degani D, et al (1997) Eightyone percent event-free survival in advanced Burkitt lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 8:77–81
Corbacioglu S, Eber S, Gungor T, et al (2003) Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. J Pediatr Hematol Oncol 25:327–329
de Vries MJ, Veerman AJ, Zwaan CM (2004) Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin lymphoma. Br J Haematol 125:414–415
Cairo MS, Sposto R, Hoover-Regan M, et al (2003) Childhood and adolescent large-cell lymphoma (LCL): a review of the Children’s Cancer Group experience. Am J Hematol 72:53–63
Laver JH, Mahmoud H, Pick TE, et al (2002) Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma 43:105–109
Patte C, Auperin A, Bergeron C, et al (2002) Large Bcell lymphoma (LBCL) in children: similarities and differences with Burkitt (BL) in children and LBCL in adults. Experience of the SFOP LMB89 study. Ann Oncol 13:110 (abstract #379)
Laver JH, Weinstein HJ, Hutchison RE, et al (2001) Lineage-specific differences in outcome for advanced stage large cell lymphoma in children and adolescents: results of a randomized phase III Pediatric Oncology Group Trial. Blood 98:345a (abstract)
Alizadeh AA, Eisen MB, Davis RE, et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511
Coiffier B, Lepage E, Briere J, et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242
Pfreundschuh MG, Trumper L, Ma D, et al (2004) Randomized intergroup trial of first line treatment for patients <= 60 years with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab — early stopping after the first interim analysis. Proc ASCO 23:6500 (abstract)
Savage KJ, Monti S, Kutok JL, et al (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871–3879
Patte C, Gerrard M, Auperin A, et al (2003) Results of the randomised international trial FAB LMB 96 for the “intermediate risk” childhood and adolescent B-cell lymphoma: reduced therapy is efficacious. Proc ASCO 22:796 (abstract)
Seidemann K, Tiemann M, Lauterbach I, et al (2003) Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol 21:1782–1789
Lones MA, Perkins SL, Sposto R, et al (2000) Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children’s Cancer Group report. J Clin Oncol 18:3845–3853
Stein H, Mason DY, Gerdes J, et al (1985) The expression of the Hodgkin disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848–858
Rimokh R, Magaud JP, Berger F, et al (1989) A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (‘Ki-1 lymphoma’). Br J Haematol 71:31–36
Morris SW, Kirstein MN, Valentine MB, et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin lymphoma. Science 263:1281–1284
Chott A, Kaserer K, Augustin I, et al (1990) Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases. Am J Surg Pathol 14:439–448
Delsol G, Al Saati T, Gatter KC, et al (1988) Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 130:59–70
Nakamura S, Takagi N, Kojima M, et al (1991) Clinicopathologic study of large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) among the Japanese. Cancer 68:118–129
Greer JP, Kinney MC, Collins RD, et al (1991) Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 9:539–547
Shiota M, Nakamura S, Ichinohasama R, et al (1995) Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 86:1954–1960
Gascoyne RD, Aoun P, Wu D, et al (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913–3921
Falini B, Pileri S, Pizzolo G, et al (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1–14
Stein H, Foss HD, Durkop H, et al (2000) CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96:3681–3695
Fraga M, Brousset P, Schlaifer D, et al (1995) Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 103:82–89
Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al (1998) ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91:2076–2084
Jaffe ES (2001) Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 2001;14:219–228
Willemze R, Beljaards RC (1993) Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 28:973–980
Vergier B, Beylot-Barry M, Pulford K, et al (1998) Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol 22:1192–1202
DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME (1996) The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 87:3437–3441
Drexler HG, Gignac SM, von Wasielewski R, et al (2000) Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 14:1533–1559
Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20:5623–5637
Gascoyne RD, Adomat SA, Krajewski S, et al (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin lymphoma. Blood 90:244–251
Murphy SB (1994) Pediatric lymphomas: recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood. Ann Oncol 5:31–33
Seidemann K, Tiemann M, Schrappe M, et al (2001) Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 97:3699–3706
Sandlund JT, Pui CH, Santana VM, et al (1994) Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin lymphoma. J Clin Oncol 12:895–898
Williams DM, Hobson R, Imeson J, et al (2002) Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol 117:812–820
Massimino M, Spreafico F, Luksch R, Giardini R (2001) Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL). Med Pediatr Oncol 37:97–102
Brugieres L, Deley MC, Pacquement H, et al (1998) CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 92:3591–3598
Suzuki R, Kagami Y, Takeuchi K, et al (2000) Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993–3000
Sandlund JT, Pui CH, Roberts WM, et al (1994) Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood 84:2467–2471
Cairo MS, Krailo MD, Morse M, et al (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate („Orange“) in children with advanced non-lymphoblastic non-Hodgkin lymphoma. A Children’s Cancer Group report. Leukemia 16:594–60
Reiter A, Schrappe M, Tiemann M, et al (1994) Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 12:899–908
Mora J, Filippa DA, Thaler HT, et al (2000) Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center. Cancer 88:186–197
Abromowitch M, Sposto R, Perkins SL, et al (2002) Preliminary results of CCG-5941: a pilot study in children and adolescents with anaplastic large cell lymphoma. Ann Oncol 13:erratum
Fanin R, Silvestri F, Geromin A, et al (1996) Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/− radiotherapy) and autologous bone marrow transplantation. Blood 87:1243–1248
Sternberg C (1916) Leukosarkomatose and myelobastenleukaamie. Beitr Pathol 61:75
Barcos MGP, Lukes RJ (1975) Malignant lymphoma of the convoluted lymphocytes: a new entity of possible T-cell type. In: Sinks L, Godden J (eds) Conflicts in Childhood Cancer: An Evaluation of Current Management. Liss, New York, p 147
Amylon MD, Shuster J, Pullen J, et al (1999) Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 13:335–342
Tubergen DG, Krailo MD, Meadows AT, et al (1995) Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin lymphoma: a Childrens Cancer Group study. J Clin Oncol 13:1368–1376
Mora J, Filippa DA, Qin J, Wollner N (2003) Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer 98:1283–1291
Reiter A, Schrappe M, Ludwig WD, et al (2000) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 95:416–421
Thomas DA, Kantarjian HM (2001) Lymphoblastic lymphoma. Hematol Oncol Clin North Am 15:51–95
Colgan JP, Andersen J, Habermann TM, et al (1994) Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin lymphoma. Leuk Lymphoma 15:291–296
Hoelzer D, Gokbuget N, Digel W, et al (2002) Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99:4379–4385
Cairo MS, Raetz E, Perkins SL (2003) Non-Hodgkin lymphoma in children. In: Kufe DW, Pollock RE, Weichselbaum RR, et al (eds) Cancer Medicine (6th edition). Decker, London, pp 2337–2348
Sandlund JT, Downing JR, Crist WM (1996) Non-Hodgkin lymphoma in childhood. N Engl J Med 334:1238–1248
Perkins SL (2000) Work-up and diagnosis of pediatric non-Hodgkin lymphomas. Pediatr Dev Pathol 3:374–390
Pilozzi E, Muller-Hermelink HK, Falini B, et al (1999) Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 188:267–270
Hojo H, Sasaki Y, Nakamura N, Abe M (2001) Absence of somatic hypermutation of immunoglobulin heavy chain variable region genes in precursor B-lymphoblastic lymphoma: a study of four cases in childhood and adolescence. Am J Clin Pathol 116:673–682
Link MP, Donaldson SS, Berard CW, et al (1990) Results of treatment of childhood localized non-Hodgkin lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 322:1169–1174
Anderson J, Jenkin R, Wilson J, et al (1993) Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 11:1024–1032
Wollner N, Burchenal JH, Lieberman PH, et al (1976) Non-Hodgkin lymphoma in children. A comparative study of two modalities of therapy. Cancer 37:123–134
Anderson J, Wilson J, Jenkin D, et al (1983) Childhood non-Hodgkin lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 308:559–565
Asselin B, Shuster JJ, Amylon M, et al (2001) Improved event-free survival (EFS) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group (POG) study. Proc Am Soc Clin Oncol 20:1464 (abstract)
Millot F, Suciu S, Philippe N, et al (2001) Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increasedrisk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 19:1935–1942
Weinstein HJ, Cassady JR, Levey R (1983) Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1:537–541
Hvizdala EV, Berard C, Callihan T, et al (1988) Lymphoblastic lymphoma in children — a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study. J Clin Oncol 6:26–33
Eden OB, Hann I, Imeson J, et al (1992) Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children’s Cancer Study Group (UKCCSG) protocol 8503. Br J Haematol 82:310–316
Abromowitch M, Sposto R, Prkins S, et al (2000) Outcome of Children’s Cancer Group (CCG) 5941: A pilot study for the treatment of newly diagnosed pediatric patients with disseminated lymphoblastic lymphoma. Proc Am Soc Clin Oncol 19:2295 (abstract)
Coleman CN, Picozzi VJ Jr, Cox RS, et al (1986) Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4:1628–1637
Morel P, Lepage E, Brice P, et al (1992) Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 10:1078–1085
Zinzani PL, Bendandi M, Visani G, et al (1996) Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma 23:577–582
Bouabdallah R, Xerri L, Bardou VJ, et al (1998) Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: pa report on 62 patients from a single center. Ann Oncol 9:619–625
Sweetenham JW, Santini G, Qian W, et al (2001) Highdose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927–2936
Levine JE, Harris RE, Loberiza FR, Jr., et al (2003) A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101:2476–2482
Falini B, Pileri S, Zinzani PL, et al (1999) ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93:2697–2706
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Patte, C., Bleyer, A., Cairo, M.S. (2007). Non-Hodgkin Lymphoma. In: Bleyer, W.A., Barr, R.D. (eds) Cancer in Adolescents and Young Adults. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68152-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-540-68152-6_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-40842-0
Online ISBN: 978-3-540-68152-6
eBook Packages: MedicineMedicine (R0)